• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Perforomist (formoterol fumarate) Inhalation Solution

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2012

 

Summary View

5 WARNINGS AND PRECAUTIONS 

5.8 Immediate Hypersensitivity Reactions
  • new section added

6 ADVERSE REACTIONS

6.3 Postmarketing Experience 
  • Anaphylactic reactions, urticaria, angioedema (presenting as face, lip, tongue, eye, pharyngeal, or mouth edema), rash, and bronchospasm